Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
Jacques-Eric GottenbergJacques MorelElodie PerrodeauThomas BardinBernard CombeMaxime DougadosRene-Marc FlipoAlain SarauxThierry SchaeverbekeJean SibiliaMartin SoubrierOlivier VittecoqGabriel BaronArnaud ConstantinPhilippe RavaudXavier Mariettenull nullPublished in: BMJ (Clinical research ed.) (2019)
Among adults with refractory rheumatoid arthritis followed-up in routine practice, rituximab and tocilizumab were associated with greater improvements in outcomes at two years compared with abatacept.
Keyphrases
- rheumatoid arthritis
- diffuse large b cell lymphoma
- disease activity
- chronic lymphocytic leukemia
- ankylosing spondylitis
- hodgkin lymphoma
- interstitial lung disease
- primary care
- healthcare
- rheumatoid arthritis patients
- clinical practice
- quality improvement
- type diabetes
- juvenile idiopathic arthritis
- metabolic syndrome
- adipose tissue